AstraZeneca Hits Mylan With Patent Suit Over Blood Thinner
Mylan has infringed five of AstraZeneca's patents by filing an abbreviated new drug application with the U.S. Food and Drug Administration to make a generic version of AstraZeneca's blood thinner Brilinta,...To view the full article, register now.
Already a subscriber? Click here to view full article